Company profile
Typewriter Therapeutics
Biotech developing RNA-based gene writing medicines using target-primed reverse transcription, delivered by lipid nanoparticles to insert whole therapeutic genes. The company emerged from stealth with this Series A, focusing on in vivo CAR T and genetic liver diseases, with first non-human primate studies planned for late 2026. It has research operations in Cambridge and Tokyo.
- Location
- Cambridge, MA
- Website
- typewritertx.com
Latest known funding
Series A round
- Capital
- $56M
- Announced
- Sep 2, 2026